HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (âSTRATAâ or the âCompanyâ) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended June 30, 2025, and provides a corporate update.
Related Questions
What was the yearâoverâyear revenue growth and how does it compare to the prior quarter?
What guidance did the company provide for the fullâyear 2025 outlook, including revenue, EBITDA, and cash flow?
Did the company announce any new product launches, FDA approvals, or regulatory milestones that could affect future revenue?
How does the updated guidance impact the company's valuation multiples (P/E, EV/EBITDA) relative to peers?
What is the current cash position and runway, and are there any planned capital expenditures or acquisitions?
How does the company's product pipeline and upcoming milestones compare to competitors in the dermatology space?
What are the potential risks or uncertainties highlighted in the corporate update (e.g., regulatory, supplyâchain, reimbursement)?
Are there any changes to the management team or board that could influence execution of the strategy?
What is the implied impact of the reported results on the companyâs longâterm growth outlook and market share in dermatology?
Did management discuss any changes in market strategy, pricing, or reimbursement that could affect margins?
What impact might the announced corporate update have on shortâterm stock volatility and trading volume?
How does STRATA's gross margin and operating expense trends compare to its historical trends and industry averages?
Did STRATA beat or miss consensus estimates for revenue and EPS in Q2 2025?
What were the earnings per share (EPS) and net income figures, and how do they compare to analyst expectations?
Did the company announce any share repurchase program, dividend, or other shareholderâreturn initiatives?